Asylia Diagnostics is a diagnostics technology platform intended to provide safer immunotherapy for cancer patients. We collect molecular and real-world evidence data from patients treated with investigational drugs in clinical trials and patients treated by the standard of care. We then use our data platform and AI-powered technology to transform these highly heterogeneous patient populations into well-defined subgroups that share common molecular and immuno-pathophysiology profiles. By doing this, we are able to identify highly specific biomarkers and novel drug targets. We then use discovered endotypes, biomarkers, and drug targets to develop patient stratification, enrichment, and indication expansion strategies, early hits/leads for the therapeutic pipeline, and eventually complex theranostic products together with our biopharma and IVD partners.
